Amylyx Pharmaceuticals (AMLX) Stock Overview
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AMLX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amylyx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.41 |
| 52 Week High | US$41.14 |
| 52 Week Low | US$10.83 |
| Beta | -0.12 |
| 1 Month Change | -16.04% |
| 3 Month Change | 106.83% |
| 1 Year Change | 143.50% |
| 3 Year Change | 75.38% |
| 5 Year Change | n/a |
| Change since IPO | 79.36% |
Recent News & Updates
Narrative Update • Sep 17
AMLX: LUCIDITY Success Will Drive Undervalued Post Bariatric Hypoglycemia Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $42, up from $25.56 in the prior fair value estimate, reflects analysts' views that strong Phase 3 LUCIDITY data for avexitide and a clearer commercial path in post-bariatric hypoglycemia support higher projected revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY results for avexitide and what those data could mean for valuation, revenue potential, and execution risks in post-bariatric hypoglycemia.
Narrative Update • Sep 03
AMLX: Positive PBH Phase 3 Results Will Drive Bullish Repricing
Amylyx Pharmaceuticals' consensus analyst price target has shifted higher from about $37.58 to $57.00 as analysts respond to avexitide's Phase 3 LUCIDITY data that showed strong efficacy, clean tolerability, and what they describe as a sizable post-bariatric hypoglycemia market opportunity. Analyst Commentary Bullish analysts describe the LUCIDITY readout as a major inflection point for Amylyx Pharmaceuticals, with multiple firms revisiting their models for avexitide in post bariatric hypoglycemia.Recent updates
Narrative Update • Sep 17
AMLX: LUCIDITY Success Will Drive Undervalued Post Bariatric Hypoglycemia Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $42, up from $25.56 in the prior fair value estimate, reflects analysts' views that strong Phase 3 LUCIDITY data for avexitide and a clearer commercial path in post-bariatric hypoglycemia support higher projected revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY results for avexitide and what those data could mean for valuation, revenue potential, and execution risks in post-bariatric hypoglycemia.Narrative Update • Sep 03
AMLX: Positive PBH Phase 3 Results Will Drive Bullish Repricing
Amylyx Pharmaceuticals' consensus analyst price target has shifted higher from about $37.58 to $57.00 as analysts respond to avexitide's Phase 3 LUCIDITY data that showed strong efficacy, clean tolerability, and what they describe as a sizable post-bariatric hypoglycemia market opportunity. Analyst Commentary Bullish analysts describe the LUCIDITY readout as a major inflection point for Amylyx Pharmaceuticals, with multiple firms revisiting their models for avexitide in post bariatric hypoglycemia.
Narrative Update • Aug 20
AMLX: LUCIDITY Success Will Expose Overoptimistic Hopes For PBH Commercial Rollout
Amylyx Pharmaceuticals’ updated analyst price target framework now centers on an implied fair value of $22.63 per share, with analysts citing the strong Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia and the potential for a sizable treatment opportunity as key drivers of their revised assumptions. Analyst Commentary Street research on Amylyx Pharmaceuticals has turned more constructive following the Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia, with several firms revising their valuation models and price targets to reflect the trial outcomes and the size of the potential treatment pool.Seeking Alpha • Aug 18
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Summary Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway. Despite a projected cash runway into 2028, company may need to raise capital in 2027; Cash raise possible early as today because of stock trading significantly higher. Read the full article on Seeking AlphaNarrative Update • Aug 06
AMLX: Q3 LUCIDITY Outcome Will Shape View On Undervalued Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $25.56, up from $24.40, reflects analysts' focus on the upcoming Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia and the related sales potential cited in recent research. Analyst Commentary Recent research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY study of avexitide in post bariatric hypoglycemia, with several firms updating their price targets and framing both upside potential and execution risks around this single pivotal catalyst.Narrative Update • Jul 10
AMLX: Phase 3 LUCIDITY Readout Will Drive View On Undervalued Potential
The analyst fair value estimate for Amylyx Pharmaceuticals has been adjusted from $22.20 to $24.40 as analysts reference higher Street price targets, including Guggenheim's move to $40 and the stock's inclusion as a "Best Idea." This is supported by expectations around the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia and the potential of the $6b+ US PBH market. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals focuses heavily on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia, with valuation views closely tied to how analysts frame the opportunity in the US PBH market and the stock's execution risks around this catalyst.Narrative Update • Jun 26
AMLX: Upcoming PBH Phase 3 Readout Will Drive Bullish Repricing
Amylyx Pharmaceuticals' updated analyst price target has shifted from about $32.63 to roughly $37.58, with analysts citing the stock's inclusion on select "Best Idea" lists and expectations around upcoming LUCIDITY trial results as key reasons for the change. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals highlights a cluster of upbeat views ahead of the LUCIDITY Phase 3 readout for avexitide in post-bariatric hypoglycemia.New Narrative • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Analysis Article • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...Analysis Article • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking AlphaAnalysis Article • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...Analysis Article • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking AlphaAnalysis Article • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...Analysis Article • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Shareholder Returns
| AMLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | 1.9% | -0.2% |
| 1Y | 143.5% | 47.5% | 11.9% |
Return vs Industry: AMLX exceeded the US Pharmaceuticals industry which returned 47.1% over the past year.
Return vs Market: AMLX exceeded the US Market which returned 12% over the past year.
Price Volatility
| AMLX volatility | |
|---|---|
| AMLX Average Weekly Movement | 19.7% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AMLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AMLX's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 136 | Josh Cohen | amylyx.com |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. Fundamentals Summary
| AMLX fundamental statistics | |
|---|---|
| Market cap | US$4.26b |
| Earnings (TTM) | -US$152.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-26.7x
P/E RatioIs AMLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMLX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$92.45m |
| Gross Profit | -US$92.45m |
| Other Expenses | US$59.65m |
| Earnings | -US$152.09m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AMLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 07:38 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amylyx Pharmaceuticals, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Christopher Chen | Baird |
| Joel Beatty | Baird |